Neos Kicks Off Global Indie Game Publishing Business
-New Label "IndieTech Games" Launched-
Neos has launched "IndieTech Games," a label dedicated to publishing high-quality indie games worldwide, including in Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250320035646/en/
IndieTechGames
Neos entered the game development and publishing business for Nintendo Switch in 2019, starting with the release of "Shin chan: Me and the Professor on Summer Vacation - The Endless Seven-Day Journey" in Japan in 2021. The title later expanded to Asia, Europe, and North America in the following year, and eventually to the rest of the world, achieving cumulative shipments of over 500,000 units.
The latest title, "Shin chan: Shiro and the Coal Town," has also been released globally and has been well received, following the success of its predecessor with cumulative shipments exceeding 300,000 units.
Through the sales and marketing of our in-house developed titles, we have had more opportunities to engage with games from around the world. At the same time, we have also increasingly encountered indie games that, for various reasons, have not been distributed globally.
In response, Neos has launched a new label, "IndieTech Games," to bring high-quality indie games—those that developers or rights holders are unable to publish themselves—to gamers worldwide. Leveraging our experience in game planning, development, and marketing, we will discover and showcase unique and captivating indie titles, distributing them globally in collaboration with our network of regional partners.
At "IndieTech Games," we carefully select titles that, like Neos' in-house developed games, place great importance on characters, art, and storytelling. Our goal is to create a publishing label that developers feel truly glad to work with.
At launch, we plan to release the following three titles. Details on pricing and release dates will be announced separately.
Title: PIGROMANCE
Genre: Action Puzzle
Developer/Licensor: GRAVITY (Korea)
Platform: Nintendo Switch
Rating: CERO C
Territory: Worldwide
Languages: Japanese, English, Korean, French, German, Spanish, Portuguese, Simplified Chinese, Traditional Chinese
Title: SEDAP! A Culinary Adventure
Genre: Action Adventure
Developer/Licensor: kopiforge (Singapore)
Platform: Nintendo Switch
Rating: Pending
Territory: Japan, Korea, Taiwan, Hong Kong, Southeast Asia
Languages: Japanese, English, Korean, Indonesian, Filipino, Malay, Simplified Chinese, Traditional Chinese
Title: Sunsethills
Genre: Puzzle Adventure
Developer: Cotton Game (China)
Licensor: Asmik Ace (Japan)
Platform: Nintendo Switch
Rating: Pending
Territory: Japan, Korea, Southeast Asia
Languages: Japanese, English, Korean, Simplified Chinese, Traditional Chinese
- Official X: https://x.com/indietech_games
- Official Instagram: https://www.instagram.com/indietech_games/
- Official Facebook: https://www.facebook.com/profile.php?id=61574205204129
View source version on businesswire.com: https://www.businesswire.com/news/home/20250320035646/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM and Scientek Corporation Sign Reseller Agreement to Boost Quantum Computing in Taiwan18.9.2025 10:11:00 CEST | Press release
Companies aim at fuelling the local quantum ecosystem growth and promote adoption IQM Quantum Computers and Scientek Corporation, a Taiwan-based reseller of scientific instruments and other high-technology products, today announced the signing of a strategic reseller agreement to accelerate the commercialisation of quantum computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918110284/en/ IQM and Scientek Corporation sign reseller agreement The agreement follows the installation of IQM Spark, the first full-stack superconducting quantum computer at the Taiwan Semiconductor Research Institute (TSRI). Under the reseller agreement, Scientek will sell and promote IQM’s on-premises quantum computers and cloud solutions that meet the evolving needs of universities, research institutions, and enterprises. Combining Scientek's strong market presence and customer-centric approach in Taiwan with IQM’s quantum leadership, the c
Acuity Knowledge Partners Acquires Ascent18.9.2025 09:30:00 CEST | Press release
Acuity Knowledge Partners (Acuity), a leading global provider of bespoke research, data management, analytics and AI solutions to the financial services sector, has announced that it has exchanged on the acquisition of Ascent. The transaction is expected to close on 30th September 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915732380/en/ L-R: Stewart Smythe, Chief Executive Officer, Ascent; Jon O'Donnell, Chief Operating Officer, Acuity Knowledge Partners, and Robert King, Chief Executive Officer, Acuity Knowledge Partners This strategic move significantly expands Acuity's Data and Technology Services (DTS) division and its offering of technology and AI led services and solutions. Ascent, a leading European provider of AI-powered digital transformation services, supports over 170 clients globally, with 550 data, software, and cloud specialists operating across seven European jurisdictions. “Our acquisition of Asc
Shield and PwC UK Forge Strategic Collaboration to Deliver Future-Ready Communications Compliance18.9.2025 08:00:00 CEST | Press release
Collaboration brings together Shield's AI-first platform with PwC's surveillance expertise to deliver measurable compliance outcomes Shield, a leading AI platform for digital communication governance and archiving, today announced a collaboration with PwC UK, one of the world’s most trusted professional services firms. The alliance brings together Shield’s unified, cloud-native solution with PwC’s specialist expertise in communications surveillance delivery, regulatory compliance and complex programme execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917394739/en/ Shield and PwC launch a strategic collaboration to modernize eComms surveillance with AI-driven compliance solutions for financial institutions. The collaboration is designed to support institutions as they modernise their approach to communications monitoring, helping them implement an advanced and proactive risk management approach at scale and with co
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 202518.9.2025 08:00:00 CEST | Press release
Results of the POSITIVE study assessing the treatment with tildrakizumab showed sustained improvements in skin clearance, psychological well-being, and improved partner quality of life in adults with moderate-to-severe psoriasis over two years.POSITIVE is the first real-world evidence (RWE) study in dermatology to use the WHO-5 Well-Being Index as a primary endpoint, complementing traditional measures of skin disease (PASI, PGA), quality of life (DLQI), with the assessment of psychological well-being, marking a paradigm shift towards holistic management of psoriasis.The POSITIVE study highlights Almirall’s leadership in advancing patient-centred dermatology aligned with the WHO’s health definition and recent resolution on skin diseases.Almirall’s extensive scientific contributions to EADV 2025 include 44 abstracts across key dermatological conditions including atopic dermatitis, psoriasis, actinic keratosis, and hidradenitis suppurativa, and two expert-led symposia. Almirall, S.A. (ALM
Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 318.9.2025 07:00:00 CEST | Press release
Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom